These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5676 related articles for article (PubMed ID: 3149257)

  • 21. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M; Brooker L; Leaker M; Paes B; Weitz J
    Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
    Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
    Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in thrombolytic therapy.
    Collen DC; Gold HK
    Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ; Gresalfi N; Daly D; Oberhardt B; Tate DA
    J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
    Brommer EJ
    Thromb Res; 1984 Apr; 34(2):109-15. PubMed ID: 6539513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
    Pannell R; Gurewich V
    Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolytic properties of staphylokinase.
    Matsuo O; Okada K; Fukao H; Tomioka Y; Ueshima S; Watanuki M; Sakai M
    Blood; 1990 Sep; 76(5):925-9. PubMed ID: 2118398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Thrombolytic agents: efficacy in relation to evolution time and dose].
    García Frade LJ; Torrado MC; Loren M; Navarro JL
    Rev Clin Esp; 1989 Feb; 184(2):75-9. PubMed ID: 2502822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism of thrombolytic agents in vivo.
    Collen D; Stassen JM; Stump DC; Verstraete M
    Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis.
    Ouriel K; Welch EL; Shortell CK; Geary K; Fiore WM; Cimino C
    J Vasc Surg; 1995 Nov; 22(5):593-7. PubMed ID: 7494361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase).
    Musselman DR; Tate DA; Oberhardt BJ; Abruzzini AF; Blauwet MB; Koch G; Dehmer GJ
    Am J Cardiol; 1994 Mar; 73(8):544-9. PubMed ID: 8147298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J; Yu M; Ru B
    Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
    Schneider J; Friderichs E; Günzler WA; Flohé L
    Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
    Bookstein JJ; Saldinger E
    Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 284.